Market Overview:
The global growth hormone deficiency treatment market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into pharmacological therapy, recombinant human growth hormone and human pituitary gland extracts. Pharmacological therapy dominates the global growth hormone deficiency treatment market in terms of revenue share in 2017 and is expected to maintain its dominance throughout the forecast period. This can be attributed to factors such as rising prevalence of Growth Hormone Deficiency (GHD) across globe coupled with increasing adoption rate for pharmacological therapies over other treatments options available in this space. On the basis of application, hospitals dominate the global growth hormone deficiency treatment market in terms revenue share followed by clinics.
Product Definition:
Growth hormone deficiency treatment is the use of growth hormones to treat people who do not produce enough growth hormone. Growth hormones are important because they help children grow and adults stay healthy.
Pharmacological Therapy:
Pharmacological therapy, also known as drug therapy or medication is a group of drugs used to treat diseases and disorders. The most common type of pharmacological treatment is the use of anti-depressants or anti-anxiety medications for anxiety disorders such as panic disorder, phobias, and obsessive compulsive disorder (OCD).
Recombinant Human Growth Hormone:
Recombinant human growth hormone (r-hGH) is a peptide hormone that stimulates the pituitary gland to produce GH. It is used in the treatment of children and adults who have Growth Hormone Deficiency (GHD). GHD occurs when there is a lack of production or activity of growth hormones by the brain, which leads to delayed puberty, poor linear growth, short height and an adult-sized child body shape.
Application Insights:
The clinics segment dominated the global growth hormone deficiency treatment market in 2017. This is owing to factors such as an increase in patients preferring to go for diagnosis and treatment at their preferred outpatient settings. Furthermore, a rise in the adoption of lifestyle management practices by patients that include dietary habits modification and regular exercise is expected to drive demand over the forecast period.
The hospitals segment is projected to witness lucrative growth during the forecast period due largely on an increase in GH replacement therapy usage across various hospital settings globally including burn units, endocrinology departments and surgical intensive care units among others.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in awareness about growth hormone deficiency, increasing prevalence of obesity and diabetes, and availability of effective treatment methods. Moreover, presence of key players such as Pfizer Inc.; Takeda Pharmaceuticals; BMS; Eli Lilly & Co.; Novo Nordisk A/S; Merck KGaA is expected to drive the regional demand for GH replacement therapy.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to rising geriatric population prone to various diseases coupled with growing awareness among patients suffering from GHD about available treatment options. In addition, increase in healthcare expenditure by governments along with rising investments by pharmaceutical companies will boost market development during the forecast period.
Growth Factors:
- Increasing awareness about Growth Hormone Deficiency Treatment and its benefits is expected to drive the market growth.
- Rising prevalence of Growth Hormone Deficiency is another major factor that would fuel the demand for Growth Hormone Deficiency Treatment in the coming years.
- Growing geriatric population is also anticipated to create lucrative opportunities for the market players in the near future.
- Technological advancements in Growth Hormone Deficiency Treatment therapies are likely to boost the market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Growth Hormone Deficiency Treatment Market Research Report
By Type
Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts
By Application
Hospitals, Clinics, Home Care Settings
By Companies
Sandoz International, Sanofi Aventis, Pfizer, Novo Nordisk, Teva Pharmaceutical, Ranbaxy, EMD Serono, Sun Pharmaceutical, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Growth Hormone Deficiency Treatment Market Report Segments:
The global Growth Hormone Deficiency Treatment market is segmented on the basis of:
Types
Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Home Care Settings
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sandoz International
- Sanofi Aventis
- Pfizer
- Novo Nordisk
- Teva Pharmaceutical
- Ranbaxy
- EMD Serono
- Sun Pharmaceutical
- Eli Lilly
Highlights of The Growth Hormone Deficiency Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pharmacological Therapy
- Recombinant Human Growth Hormone
- Human Pituitary Gland Extracts
- By Application:
- Hospitals
- Clinics
- Home Care Settings
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Growth Hormone Deficiency Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Growth hormone deficiency is a condition in which the body does not produce enough growth hormone. Growth hormone helps to promote growth and development in children and adults. Treatment for growth hormone deficiency typically includes medication, surgery, or a combination of both.
Some of the major players in the growth hormone deficiency treatment market are Sandoz International, Sanofi Aventis, Pfizer, Novo Nordisk, Teva Pharmaceutical, Ranbaxy, EMD Serono, Sun Pharmaceutical, Eli Lilly.
The growth hormone deficiency treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Growth Hormone Deficiency Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Growth Hormone Deficiency Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Growth Hormone Deficiency Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Growth Hormone Deficiency Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Growth Hormone Deficiency Treatment Market Size & Forecast, 2018-2028
4.5.1 Growth Hormone Deficiency Treatment Market Size and Y-o-Y Growth
4.5.2 Growth Hormone Deficiency Treatment Market Absolute $ Opportunity
Chapter 5 Global Growth Hormone Deficiency Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Growth Hormone Deficiency Treatment Market Size Forecast by Type
5.2.1 Pharmacological Therapy
5.2.2 Recombinant Human Growth Hormone
5.2.3 Human Pituitary Gland Extracts
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Growth Hormone Deficiency Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Growth Hormone Deficiency Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Home Care Settings
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Growth Hormone Deficiency Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Growth Hormone Deficiency Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Growth Hormone Deficiency Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Growth Hormone Deficiency Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Growth Hormone Deficiency Treatment Market Size Forecast by Type
9.6.1 Pharmacological Therapy
9.6.2 Recombinant Human Growth Hormone
9.6.3 Human Pituitary Gland Extracts
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Growth Hormone Deficiency Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Home Care Settings
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Growth Hormone Deficiency Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Growth Hormone Deficiency Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Growth Hormone Deficiency Treatment Market Size Forecast by Type
10.6.1 Pharmacological Therapy
10.6.2 Recombinant Human Growth Hormone
10.6.3 Human Pituitary Gland Extracts
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Growth Hormone Deficiency Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Home Care Settings
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Growth Hormone Deficiency Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Growth Hormone Deficiency Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Growth Hormone Deficiency Treatment Market Size Forecast by Type
11.6.1 Pharmacological Therapy
11.6.2 Recombinant Human Growth Hormone
11.6.3 Human Pituitary Gland Extracts
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Growth Hormone Deficiency Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Home Care Settings
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Growth Hormone Deficiency Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Growth Hormone Deficiency Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Growth Hormone Deficiency Treatment Market Size Forecast by Type
12.6.1 Pharmacological Therapy
12.6.2 Recombinant Human Growth Hormone
12.6.3 Human Pituitary Gland Extracts
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Growth Hormone Deficiency Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Home Care Settings
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Growth Hormone Deficiency Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Growth Hormone Deficiency Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Growth Hormone Deficiency Treatment Market Size Forecast by Type
13.6.1 Pharmacological Therapy
13.6.2 Recombinant Human Growth Hormone
13.6.3 Human Pituitary Gland Extracts
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Growth Hormone Deficiency Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Home Care Settings
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Growth Hormone Deficiency Treatment Market: Competitive Dashboard
14.2 Global Growth Hormone Deficiency Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sandoz International
14.3.2 Sanofi Aventis
14.3.3 Pfizer
14.3.4 Novo Nordisk
14.3.5 Teva Pharmaceutical
14.3.6 Ranbaxy
14.3.7 EMD Serono
14.3.8 Sun Pharmaceutical
14.3.9 Eli Lilly
